{"id":24524,"date":"2014-06-04T07:09:44","date_gmt":"2014-06-04T11:09:44","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=24524"},"modified":"2014-06-04T07:09:44","modified_gmt":"2014-06-04T11:09:44","slug":"prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524","title":{"rendered":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#8217;s Approval For Muscle Disorder Drug"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 <b>Prosensa Holding NV (NASDAQ:RNA)<\/b> on June 3, 2014 publicized the news that the U.S. Food and Drug Administration (FDA) has showed a sight of a positive signal for the company&#8217;s most advanced muscle disorder drug.<\/p>\n<p style=\"text-align: justify;\"><b>Prosensa On The Right Track To Bring Muscle Disorder Drug:<\/b><\/p>\n<p style=\"text-align: justify;\">The drug is aimed to treat patients suffering from the muscle disorder. The Netherland based medical company; Prosensa Holding NV (NASDAQ:RNA) on Tuesday, June 3, 2014 stated that it is planning to perform two more studies and will apply to the U.S. marketing for at the end of this year. However, the company will also ask for European approval in some years, stated the company.<\/p>\n<p style=\"text-align: justify;\"><b>Drug May Win The U.S. Approval By 2015:<\/b><\/p>\n<p style=\"text-align: justify;\">An analyst of KBC Securities, Jan De Kerpel commented that Prosensa&#8217;s medicine to treat DMD (Duchene muscular dystrophy) may snatch the U.S. sanction in 2015, similarly like Sarepta Therapeutics Inc&#8217;s Eteplirsen drug. Moreover, the drug can also fetch huge amount of sales of almost $1.36 billion and rank itself among the topmost medicine in muscular disorder issues. However, the company has to pay 200,000 Euros every year for patent. The analyst also added that the treatment of Prosensa Holding NV (NASDAQ:RNA) will gain better appreciation than Sarepta&#8217;s drug.<\/p>\n<p style=\"text-align: justify;\"><b>Cause Of Muscle Disorder:<\/b><\/p>\n<p style=\"text-align: justify;\">DMD is caused due to insufficient production of a protein called dystrophic; the drug is designed in such a way which will augment the production of that very protein inside the body. In recent months, the drug has received tremendous positive signals from the regulators. The company in the month of January announced that despite of few failures in producing the drug, Prosensa will carry out the research work to ensure the successful completion of drisapersen.<\/p>\n<p style=\"text-align: justify;\">\u00a0At the beginning of this month, GlaxoSmithKline Plc, partnered with Prosensa Holding NV (NASDAQ:RNA) gave the right to the company, ending the 2009 collaboration agreement. However, the company now needs to focus more on trials in order to make the drug a successful one.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Prosensa Holding NV (NASDAQ:RNA) on June 3, 2014 publicized the news that the U.S. Food and Drug Administration (FDA) has [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24526,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5981,7072,5980],"stock_ticker":[],"class_list":["post-24524","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqrna","tag-prosensa-holding-nv","tag-prosensa-holding-nv-nasdaqrna","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#039;s Approval For Muscle Disorder Drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#039;s Approval For Muscle Disorder Drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Prosensa Holding NV (NASDAQ:RNA) on June 3, 2014 publicized the news that the U.S. Food and Drug Administration (FDA) has [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-04T11:09:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"530\" \/>\n\t<meta property=\"og:image:height\" content=\"298\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#8217;s Approval For Muscle Disorder Drug\",\"datePublished\":\"2014-06-04T11:09:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg\",\"keywords\":[\"NASDAQ:RNA\",\"Prosensa Holding NV\",\"Prosensa Holding NV (NASDAQ:RNA)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\",\"name\":\"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA's Approval For Muscle Disorder Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg\",\"datePublished\":\"2014-06-04T11:09:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg\",\"width\":530,\"height\":298},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#8217;s Approval For Muscle Disorder Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA's Approval For Muscle Disorder Drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524","og_locale":"en_US","og_type":"article","og_title":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA's Approval For Muscle Disorder Drug - Wall Street PR","og_description":"Boston, MA 06\/04\/2014 (wallstreetpr) \u2013 Prosensa Holding NV (NASDAQ:RNA) on June 3, 2014 publicized the news that the U.S. Food and Drug Administration (FDA) has [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-04T11:09:44+00:00","og_image":[{"width":530,"height":298,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#8217;s Approval For Muscle Disorder Drug","datePublished":"2014-06-04T11:09:44+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg","keywords":["NASDAQ:RNA","Prosensa Holding NV","Prosensa Holding NV (NASDAQ:RNA)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524","url":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524","name":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA's Approval For Muscle Disorder Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg","datePublished":"2014-06-04T11:09:44+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/prosensa.jpg","width":530,"height":298},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/prosensa-holding-nv-nasdaqrna-in-the-right-track-to-get-the-fdas-approval-for-muscle-disorder-drug-24524#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Prosensa Holding NV (NASDAQ:RNA) In The Right Track To Get The FDA&#8217;s Approval For Muscle Disorder Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=24524"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/24524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24526"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=24524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=24524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=24524"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=24524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}